Drug intelligence / Profile preview

PD-0325901 + palbociclib

Development stage: Unknown
Lead developer: Dana-Farber Cancer Institute
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of PD-0325901, a MEK1/2 inhibitor, and palbociclib, a selective CDK4/6 inhibitor. This combination targets multiple signaling pathways simultaneously and is being investigated primarily for the treatment of KRAS-mutant cancers, particularly non-small cell lung cancer (NSCLC). The rationale is that dual inhibition may prevent the development of resistance mechanisms that typically emerge with single-agent therapies.

Targets

MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)CDK6 (Cyclin-dependent kinase 6)CDK4 (Cyclin-dependent kinase 4)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)

Beyond the preview

Go deeper on PD-0325901 + palbociclib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-0325901 + palbociclib.

Explore the full profile